OnCusp Therapeutics Raises $100M in Series A Funding
New York-based biotech startup OnCusp Therapeutics has successfully secured $100 million in a Series A funding round. The round was led by prominent investors Novo Holdings, F-Prime Capital, and OrbiMed. OnCusp Therapeutics, which specializes in the development of innovative therapeutics, plans to utilize the funding to advance its research and development efforts.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
